Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia

Blood Reviews

Volumn 28, Issue 5, 2014, Pages 179-187

  Mathisen, Michael S ^a   Kantarjian, Hagop M ^a   Cortes, Jorge ^a   Jabbour, Elias J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bosutinib; Chronic myeloid leukemia; Dasatinib; Imatinib; Nilotinib; Ponatinib; Tyrosine kinase inhibitors

Indexed keywords

BCR ABL PROTEIN; BOSUTINIB; CYTARABINE; DASATINIB; IMATINIB; NILOTINIB; PEGINTERFERON ALPHA2A; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTERY THROMBOSIS; ARTHRALGIA; ASTHENIA; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER RESISTANCE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC MYELOID LEUKEMIA; COMORBIDITY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG CHOICE; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG MONITORING; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DRY SKIN; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LEUKEMIA RELAPSE; LIVER TOXICITY; MEDICATION COMPLIANCE; MINIMAL RESIDUAL DISEASE; MUSCLE CRAMP; MYALGIA; NAUSEA; OVERALL SURVIVAL; PANCREATITIS; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PULMONARY HYPERTENSION; QT PROLONGATION; RASH; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; DISEASE MANAGEMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, CHRONIC-PHASE; RETREATMENT; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMORBIDITY; DISEASE MANAGEMENT; DRUG COSTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, CHRONIC-PHASE; PROTEIN KINASE INHIBITORS; RETREATMENT; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84906937473     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2014.06.001     Document Type: Review

References (79)

1. Hehlmann R., Heimpel H., Hasford J., Kolb H.J., Pralle H., Hossfeld D.K., et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood 1993, 82:398-407.
2. Kantarjian H.M., Smith T.L., O'Brien S., Beran M., Pierce S., Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. Ann Intern Med 1995, 122:254-261.
3. Guilhot F., Chastang C., Michallet M., Guerci A., Harousseau J.L., Maloisel F., et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997, 337:223-229.
4. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR-ABL positive cells. Nat Med 1996, 2:561-566.
5. Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002, 346:645-652.
6. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
7. Hochhaus A., O'Brien S.G., Guilhot F., Druker B.J., Branford S., Foroni L., et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009, 23:1054-1061.
8. Deininger M., O'Brien S.G., Guilhot F., Goldman J., Hochhaus A., Hughes T.P., et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib. ASH Annual Meeting Abstracts 2009, 114:1126.
9. de Lavallade H., Apperley J.F., Khorashad J.S., Milojkovic D., Reid A.G., Bua M., et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008, 26:3358-3363.
10. Soverini S., Colarossi S., Gnani A., Rosti G., Castagnetti F., et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006, 12:7374-7379.
11. Jabbour E., Kantarjian H., Jones D., Talpaz M., Bekele N., O'Brien S., et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006, 20:1767-1773.
12. Cortes J., Jabbour E., Kantarjian H., Yin C.C., Shan J., O'Brien S., et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 2007, 110:4005-4011.
13. Sprycel (dasatinib) package insert 6/2013, [Princeton, NJ. Bristol-Myers Squibb Company].
14. Tasigna (nilotinib) package insert 1/2014, [East Hanover, NJ. Novartis Pharmaceuticals Corporation].
15. Kantarjian H., Shah N.P., Hochhaus A., Cortes J., Shah S., Avala M., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362:2260-2270.
16. Saglio G., Kim D.W., Issaragrisil S., le Coutre P., Etienne G., Lobo C., et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010, 362:2251-2259.
17. Bosulif (bosutinib) package insert 9/2013, [New York, New York. Pfizer Labs].
18. O'Hare T., Shakespeare W.C., Zhu X., Eide C.A., Rivera V.M., Wang F., et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009, 16:401-412.
19. Jabbour E., Kantarjian H.M., Saglio G., Steegmann J.L., Shah N.P., Boque C., et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014, 123:494-500.
20. Radich J.P., Kopecky K.J., Appelbaum F.R., Kamel-Reid S., Malnassy G., Paietta E., et al. A randomized trial of dasatinib 100mg versus imatinib 400mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood 2012, 120:3898-3905.
21. Larson R.A., Hochhaus A., Clark R.E., Etienne G., Kim D.-W., Flinn I.W., et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow up. Leukemia 2012, 26:2197-2203.
22. Cortes J.E., Kim D.W., Kantarjian H.M., Brummendorf T.H., Dyagil I., Griskevicius L., et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012, 30:3486-3492.
23. Cortes J.E., Baccarani M., Guilhot F., Druker B.J., Kim D.W., Pane F., et al. Phase III, randomized, open-label study of daily imatinib mesylate 400mg versus 800mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010, 28:424-430.
24. Preudhomme C., Guilhot J., Nicolini F.E., Guerci-Bresler A., Rigal-Huguet F., Maloisel F., et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010, 363:2511-2521.
25. Cortes J., Quintas-Cardama A., Jones D., Ravandi F., Garcia-Manero G., Verstovsek S., et al. Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. Cancer 2011, 117:572-580.
26. Hehlmann R., Lauseker M., Jung-Munkwitz S., Leitner A., Muller M.C., Pletsch U., et al. Tolerability-adapted imatinib 800mg/d versus 400mg/d versus 400mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011, 29:1634-1642.
27. Montani D., Bergot E., Gunther S., Savale L., Bergeron A., Bourdin A., et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012, 125:2128-2137.
28. Quintas-Cardama A., Han X., Kantarjian H., Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 2009, 114:261-263.
29. Quintas-Cardama A., Kantarjian H., Ravandi F., O'Brien S., Thomas D., Vidal-Senmache G., et al. Bleeding diathesis in patients with chronic myeloid leukemia receiving dasatinib therapy. Cancer 2009, 115:2482-2490.
30. Quintas-Cardama A., De Souza Santos F.P., Kantarjian H., O'Brien S., Faderl S., Awais A., et al. Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Cancer 2009, 115:3935-3943.
31. Kim T.D., le Coutre P., Schwarz M., Grille P., Levitin M., Fateh-Moghadam S., et al. Clinical cardiac safety profile of nilotinib. Haematologica 2012, 97:883-889.
32. Quintas-Cardama A., Kantarjian H., Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk 2012, 12:337-340.
33. Smith T.J., Hillner B.E. Bending the cost curve in cancer care. N Engl J Med 2011, 364:2060-2065.
34. Kantarjian H.M., Fojo T., Mathisen M., Zwelling L.A. Cancer drugs in the United States: justum pretium-the just price. J Clin Oncol 2013, 31:3600-3604.
35. Experts in Chronic Myeloid Leukemia The price of drugs for chronic myeloid leukemia is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013, 121:4439-4442.
36. Gambacorti-Passerini C., Antolini L., Mahon X., Guilhot F., Deininger M., Fava C., et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011, 103:553-561.
37. Gleevec (imatinib) package insert 10/2013, [East Hanover, NJ. Novartis Pharmaceuticals Corporation].
38. Baccarani M., Deininger M.W., Rosti G., Hochhaus A., Soverini S., Apperley J.F., et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013, 122:872-884.
39. O'Brien S., Radich J.P., Abboud C.N., Akhtari M., Altman J.K., Berman E., et al. Chronic myelogenous leukemia, version 1.2014. J Natl Compr Canc Netw 2013, 11:1327-1340.
40. Testoni N., Marzocchi G., Luatti S., Amabile M., Baldazzi C., Stacchini M., et al. Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. Blood 2009, 114:4939-4943.
41. Kantarjian H., Cortes J. Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitors. J Clin Oncol 2011, 29:1512-1516.
42. Kantarjian H.M., Shan J., Jones D., O'Brien S., Rios M.B., Jabbour E., et al. Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. J Clin Oncol 2009, 27:3659-3663.
43. Marin D., Ibrahim A.R., Lucas C., Gerrard G., Wang L., Szydlo R.M., et al. Assessment of BCR-ABL1 transcript levels at 3months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012, 30:232-238.
44. Jain P., Kantarjian H., Nazha A., O'Brien S., Jabbour E., Romo C.G., et al. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood 2013, 121:4867-4874.
45. Neelakantan P., Gerrard G., Lucas C., Milojkovic D., May P., Wang L., et al. Combining BCR-ABL1 transcript level at 3 and 6months in chronic myeloid leukemia: implications for early intervention strategies. Blood 2013, 121:3739-3742.
46. Nazha A., Kantarjian H., Jain P., Romo C., Jabbour E., Quintas-Cardama A., et al. Assessment at 6months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3months. Haematologica 2013, 98:1686-1688.
47. Branford S., Roberts N., Yeung D.T., Altamura H., Parker W.T., Hughes T.P. Any BRC-ABL reduction below 10% at 6months of therapy significantly improves outcome for CML patients with a poor response at 3months. Blood (ASH Annual Meeting Abstracts) 2013, 122. [Abstract 254].
48. Osterberg L., Blaschke T. Adherence to medication. N Engl J Med 2005, 353:487-497.
49. Benner J.S., Glynn R.J., Mogun H., Neumann P.J., Weinstein M.C., Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002, 288:455-461.
50. Dusetzina S.B., Winn A.N., Abel G.A., Huskamp H.A., Keating N.L. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 2014, 32:306-311.
51. Marin D., Bazeos A., Mahon F.X., Eliasson L., Milojkovic D., Bua M., et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010, 28:2381-2388.
52. Ibrahim A.R., Eliasson L., Apperley J.F., Milojkovic D., Bua M., Szydlo R., et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 2011, 117:3733-3736.
53. Wu E.Q., Johnson S., Beaulieu N., Arana M., Bollu V., Guo A., et al. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin 2010, 26:61-69.
54. Jabbour E.J., Kantarjian H., Eliasson L., Cornelison A.M., Marin D. Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol 2012, 87:687-691.
55. Marin D. Patient with chronic myeloid leukemia in complete cytogenetic response: what does it mean, and what does one do next?. J Clin Oncol 2014, 32:379-384.
56. Jabbour E., Kantarjian H.M., O'Brien S., Shan J., Quintas-Cardama A., Garcia-Manero G., et al. Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?. J Clin Oncol 2011, 29:4260-4265.
57. Cortes J.E., De Souza C.A., Lopez J.L., Ayala M., Bullorsky E., Huang X., et al. Switching to nilotinib in patients with chronic myeloid leukemia in chronic phase with suboptimal cytogenetic response on imatinib: first results of the LASOR trial. Blood (ASH Annual Meeting Abstracts) 2013, 122:95.
58. Leber B., Cervantes F., Spector N., Lipton J.H., Etienne G., Pasquini R., et al. Achievement and maintenance of deeper molecular response by switching to nilotinib in patients with chronic myeloid leukemia in chronic phase with residual disease on long-term imatinib: ENESTcmr 36-month follow up. Blood (ASH Annual Meeting Abstracts) 2013, 94.
59. Shah N.P., Kim D.W., Kantarjian H., Rousselot P., Llacer P.E., Enrico A., et al. Potent, transient inhibition of BCR-ABL with dasatinib 100mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010, 95:232-240.
60. Kantarjian H.M., Giles F.J., Bhalla K.N., Pinilla-Ibarz J., Larson R.A., Gattermann N., et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow up results. Blood 2011, 117:1141-1145.
61. Cortes J.E., Kantarjian H.M., Brummendorf T.H., Kim D.W., Turkina A.G., Shen Z.X., et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011, 118:4567-4576.
62. Jabbour E., Kantarjian H.M., Jones D., Shan J., O'Brien S., Reddy N., et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose therapy. Blood 2009, 113:2154-2160.
63. Kantarjian H., Pasquini R., Levy V., Jootar S., Holowiecki J., Hamerschlak N., et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009, 115:4136-4147.
64. Zhou T., Commodore L., Huang W.S., Wang Y., Thomas M., Keats J., et al. Structural mechanism of the pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 2011, 77:1-11.
65. Cortes J.E., Kim D.W., Pinilla-Ibarz J., le Coutre P., Paquette R., Chuah C., et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013, 369:1783-1796.
66. Jabbour E., Branford S., Saglio G., Jones D. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 2011, 117:1800-1811.
67. Muller M.C., Cortes J.E., Kim D.W., Druker B.J., Erben P., Pasquini R., et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 2009, 114:4944-4953.
68. Hughes T., Saglio G., Branford S., Soverini S., Kim D.W., Muller M.C., et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009, 27:4204-4210.
69. Kantarjian H.M., Cortes J.E., Kim D.W., Khoury H.J., Brummendorf T.H., Porkka K., et al. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood 2014, 123:1309-1318.
70. Jabbour E., Kantarjian H. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management 2012, 87:1038-1045.
71. Apperley J.F., Cortes J.E., Kim D.W., Roy L., Roboz G., Bullorsky E.O., et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START-A trial. J Clin Oncol 2009, 27:3472-3479.
72. le Coutre P.D., Giles F.J., Hochhaus A., Apperley J.F., Ossenkoppele G.J., Blakesley R., et al. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia 2012, 26:1189-1194.
73. Ohanian M., Kantarjian H.M., Quintas-Cardama A., Jabbour E., Abruzzo L., Verstovsek S., et al. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk 2014, 14:155-162.
74. Mahon F.X., Rea D., Guilhot J., Guilhot F., Huguet F., Nicolini F., et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2years: the prospective, multicenter Stop Imatinib (STIM) trial. Lancet Oncol 2010, 11:1029-1035.
75. Mahon F.X., Rea D., Guilhot J., Guilhot F., Huguet F., Nicolini F., et al. Long term follow-up after imatinib cessation for patients in deep molecular response: the updated results of the STIM1 study. Blood (ASH Annual Meeting Abstracts) 2013, 122:255.
76. Ross D.M., Branford S., Seymour J.F., Schwarer A.P., Arthur C., Yeung D.T., et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013, 122:515-522.
77. Mahon F.X., Nicolini F.E., Noel M.P., Escoffre M., Charbonnier A., Rea D., et al. Preliminary report of the STIM2 study: a multicenter stop imatinib trial for chronic phase chronic myeloid leukemia de novo patients on imatinib. Blood (ASH Annual Meeting Abstracts) 2013, 122:654.
78. Rousselot P., Charbonnier A., Cony-Makhoul P., Agape P., Nicolini F.E., Varet B., et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 2014, 32:424-430.
79. Apperley J.F. TWIST it but don't spin it. Blood 2013, 122:470-471.